Magnesium Acetate Tetrahydrate
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Magnesium Acetate Tetrahydrate
- Magnesium Acetate Tetrahydrate: From Electrolyte Supplement to Migraine Disorder
Magnesium Acetate Tetrahydrate: From Electrolyte Supplement to Migraine Disorder
One-Sentence Summary
Magnesium acetate tetrahydrate is a soluble magnesium salt used as an electrolyte source in pharmaceutical formulations and parenteral preparations, with no formally approved therapeutic indications on record in Singapore. The TxGNN model predicts it may be effective for Migraine Disorder with a score of 95.28%, driven by magnesium's well-established role in blocking NMDA receptors and suppressing cortical spreading depression. No clinical trials or publications were identified for this specific compound in migraine; however, the broader magnesium supplement class carries an American Headache Society "Probably Effective" rating for migraine prevention, providing an indirect mechanistic foundation.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No formally approved indication on record |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 95.28% |
| Evidence Level | L4 |
| Singapore Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Magnesium acetate tetrahydrate dissociates in solution to release Mg²⁺ ions, the biologically active species. Magnesium is a physiological voltage-dependent blocker of NMDA receptors: when intracellular and serum magnesium levels fall, NMDA receptors become hyperactivatable, reducing the threshold for cortical spreading depression (CSD) — the electrophysiological wave underlying migraine aura and a key initiating event in migraine headache. Beyond NMDA blockade, Mg²⁺ inhibits platelet aggregation, suppresses Substance P release from trigeminal nerve endings, and modulates serotonin (5-HT) receptor signalling — all pathways directly implicated in migraine pathogenesis.
The biological plausibility is reinforced by clinical epidemiology: serum and cerebrospinal fluid magnesium concentrations are consistently lower in migraine sufferers than in healthy controls, especially during acute attacks. This observation has motivated prospective trials with magnesium supplementation as a preventive strategy. A Phase 2 RCT of oral magnesium citrate at 600 mg/day demonstrated a statistically significant reduction in migraine attack frequency, and the American Headache Society (AHS) guidelines currently classify oral magnesium as "Probably Effective" for migraine prevention. Intravenous magnesium sulfate is also used in acute migraine management in emergency settings.
Critically, all existing clinical evidence pertains to other magnesium salt forms — citrate, oxide, sulfate — not to the acetate tetrahydrate form specifically. The TxGNN model is predicting based on the shared Mg²⁺ pharmacology, which is mechanistically reasonable, but the bioavailability, gastrointestinal tolerability, and effective dose of magnesium acetate tetrahydrate remain uncharacterised in this therapeutic context. Establishing pharmacokinetic equivalence to the clinically validated salt forms would be a prerequisite before claiming transferability of existing evidence.
Clinical Trial Evidence
Currently no related clinical trials registered for magnesium acetate tetrahydrate in migraine disorder.
Searches of ClinicalTrials.gov and ICTRP were conducted specifically for magnesium acetate tetrahydrate in migraine disorder and returned zero results. Trials investigating other magnesium salt forms in migraine exist but were outside the scope of this compound-specific query.
Literature Evidence
Currently no related literature available for magnesium acetate tetrahydrate in migraine disorder.
PubMed searches specific to magnesium acetate tetrahydrate in migraine returned zero results. The absence of literature reflects a research gap for this particular salt form, not an absence of evidence for magnesium supplementation in migraine broadly.
Safety Considerations
Please refer to the package insert for safety information. No drug interaction data, contraindications, or specific safety warnings were retrievable for magnesium acetate tetrahydrate from the current evidence pack.
As a general class consideration applicable to all magnesium salts: renal impairment significantly impairs magnesium excretion, creating risk of hypermagnesemia; chelation interactions with tetracyclines, fluoroquinolones, and bisphosphonates are well-documented for the class. These are class-level cautions and have not been formally documented for this compound in the available data.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic case for magnesium in migraine is well-grounded and supported by guideline-level evidence for the magnesium supplement class; however, no clinical or preclinical data exist specifically for magnesium acetate tetrahydrate, and the compound carries zero Singapore registrations, making progression premature without foundational characterisation work.
To proceed, the following is needed:
- Comparative oral bioavailability study of magnesium acetate tetrahydrate versus magnesium citrate and magnesium oxide (the forms with established Phase 2 RCT evidence) to determine whether existing clinical evidence is transferable
- Expanded literature search at the magnesium salt class level to build a complete indirect evidence base for migraine prevention and acute treatment
- Mechanism of action documentation from DrugBank or primary pharmacological literature to close the MOA data gap
- Safety profile characterisation including dose-ranging, renal safety threshold, and GI tolerability data
- Regulatory feasibility assessment for Singapore, given the absence of any current product registration in this jurisdiction
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.